Drug Profile
BBP 671
Alternative Names: BBP-671Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator St. Jude Childrens Research Hospital
- Developer CoA Therapeutics
- Class Neuroprotectants; Small molecules
- Mechanism of Action Pantothenate kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Pantothenate kinase-associated neurodegeneration
- No development reported Acidaemia
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Acidaemia in USA (PO)
- 03 Nov 2022 BridgeBio Pharma plans a pivotal phase II/III trial for Pantothenate kinase-associated neurodegeneration in 2024
- 26 May 2022 Pharmacodynamic and adverse events data from a phase I trial in Pantothenate kinase-associated neurodegeneration released by BridgeBio Pharma